Deal with Canary Capital for "marketing services" in October 2020, was a big red flag for me. Payment in the form of cash and options @ $7.5K per month.
K2Fly has negative net tangible assets, with intangible assets and goodwill making up over $6M in assets on the balance seet.
K2Fly also have a $3.2 M liability of future payments for the SATEVA acquisition. This liability is for 18% of all invoiced amounts for SATEVA Software products, but it includes consulting sales, which are low margin. This is a bad deal IMO.
Their gross margins have improved, and are now over 50%. However, the concern is SATEVA is incentivised to grow consulting services revenue, which is not high margin SAAS revenue.
Two trading updates in the space of a week prior to another capital raise - not a good look.
Dubber Announces Unified Call Recording and Voice AI with Zoom
I have extracted the below, from a recent article published by Stockhead.
ANP is a biotech company researching a potential treatment for Duchenne’s muscular dystrophy.
“The company has made strong progress recently but we view the next 12 months as particularly important with a large number of catalysts and events unfolding giving further clarity on costs, trial design, new indication and potential for partnering discussions to commence,” Morgans said in a research report in February.
The company is working on possible new indications for its drug candidate and could soon announce details about a pivotal European phase 3 drug trial.
ANP shares are already up 76 per cent this year to 23c.
“That’s one that’s had a good run — but it really looks like it wants to run harder.”
Morgans rates Antisense a speculative buy with a price target of 37.7c.
Like all Biotech's success is never guaranteed. However, they have recruited well and have hired the following from large med tech (Sarepta) Goolsbee and Dr. Price and most recently Dr Charmaine Gittleson from CSL.
Like all Biotechs, success is never guaranteed! However, this company have recruited well and have hired the following from a large med tech (Sarepta) Mr Goolsbee and Dr. Price and most recently Dr Charmaine Gittleson from CSL.
The company is awaiting regulatory approvals from Europe and the USA. The FDA has granted the company with a Type C guidance meeting, which is scheduled for 19 April 2021. At the meeting they will discuss the further development of ATL1102 in Duchenne muscular dystrophy (DMD) in the US. The company has advised that they will be in a position to brief shareholders on the meeting in May 2021.
The SP has seen some good gains in the last few weesk. However, I tend to agree with Morgans that the price is still under valued based on the potential market for ANP's product.
Despite a 70% rise in the SP, there is still plenty of room left for a bigger rise, if the company has a successful meeting with the FDA next week!
Q3FY21 results came yesterday and it did not disappoint
12 April 2021